KIORA PHARMACEUTICALS Reports Q1 2026 Financial Results
Ticker: KPRX · Form: 8-K · Filed: Mar 25, 2026 · CIK: 0001372514
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, pharmaceuticals
TL;DR
**KIORA PHARMACEUTICALS just dropped its Q1 2026 earnings, so expect market reaction.**
AI Summary
KIORA PHARMACEUTICALS INC filed an 8-K on March 25, 2026, under Item 2.02, to report its results of operations and financial condition. This filing includes an exhibit, EX-99.1, which is likely a press release detailing these financial results. For investors, this matters because it provides the latest financial health update, which can significantly influence the stock's valuation and future prospects.
Why It Matters
This filing provides crucial financial performance data, allowing investors to assess the company's profitability and operational efficiency, which directly impacts stock price and investment decisions.
Risk Assessment
Risk Level: medium — The risk level is medium because financial results can be volatile and significantly impact stock performance, but the filing itself is a standard disclosure.
Analyst Insight
A smart investor would immediately review the EX-99.1 press release to understand the specific financial results and compare them against analyst expectations and historical performance before making any trading decisions.
Key Numbers
- 2026-03-25 — Filing Date (Date the 8-K was filed and accepted)
- 26011 — Size of 8-K document (Indicates the length of the primary 8-K document in bytes)
- 102099 — Size of EX-99.1 (Indicates the length of the press release exhibit in bytes)
Key Players & Entities
- KIORA PHARMACEUTICALS INC (company) — Filer of the 8-K
- 0001372514 (company) — CIK of KIORA PHARMACEUTICALS INC
- 2026-03-25 (date) — Filing Date and Period of Report
Forward-Looking Statements
- KIORA PHARMACEUTICALS INC's stock price will react significantly to the details disclosed in the EX-99.1 press release. (KIORA PHARMACEUTICALS INC) — high confidence, target: 2026-03-26
- Analysts will issue updated ratings or price targets for KIORA PHARMACEUTICALS INC based on these financial results. (KIORA PHARMACEUTICALS INC) — medium confidence, target: 2026-04-01
FAQ
What specific items were reported in this 8-K filing by KIORA PHARMACEUTICALS INC?
The 8-K filing by KIORA PHARMACEUTICALS INC reported under Item 2.02: Results of Operations and Financial Condition, and Item 9.01: Financial Statements and Exhibits, on March 25, 2026.
What is the significance of Exhibit EX-99.1 mentioned in the filing?
Exhibit EX-99.1 is described as 'ex991-pressreleasedecember.htm' and is likely a press release detailing the financial results and operations, providing more context to the Item 2.02 disclosure.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 25, 2026, at 07:03:04.
What is the business address and contact number for KIORA PHARMACEUTICALS INC as listed in the filing?
The business address for KIORA PHARMACEUTICALS INC is 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024, and their contact number is 858-224-9600.
What is the SIC code for KIORA PHARMACEUTICALS INC and what does it represent?
The SIC code for KIORA PHARMACEUTICALS INC is 2834, which represents 'Pharmaceutical Preparations', indicating their primary industry.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2026-03-25 07:03:04
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
Filing Documents
- kprx-20260325.htm (8-K) — 25KB
- ex991-pressreleasedecember.htm (EX-99.1) — 100KB
- kprx-20260325_g1.jpg (GRAPHIC) — 341KB
- 0001372514-26-000025.txt ( ) — 1071KB
- kprx-20260325.xsd (EX-101.SCH) — 2KB
- kprx-20260325_lab.xml (EX-101.LAB) — 22KB
- kprx-20260325_pre.xml (EX-101.PRE) — 13KB
- kprx-20260325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Conditions
Item 2.02. Results of Operations and Financial Conditions. On March 25, 2026, Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharmaceuticals, Inc., dated as of March 25, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Chief Financial Officer (Principal financial and accounting officer) Date: March 25, 2026